How UBT251 Affects Blood Levels of Midazolam, Caffeine and Warfarin in Overweight or Obesity
Tests how UBT251 changes blood levels of other medicines in adults with overweight or obesity.
Key facts
- Who runs it
- Novo Nordisk A/S
- Where
- Cypress, United StatesSee the site
- Trial code
- NCT07710768
- U1111-1332-5554
- Registry title
- A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 44 people, planned
- Started
- 15 Jul 2026
- Expected to end
- 7 Apr 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- UBT251
- Cocktail (Warfarin/Caffeine/Midazolam)
- Record updated
- 18 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight or obesity who are otherwise generally healthy. It studies how UBT251 affects blood levels of midazolam, caffeine and warfarin.
- Age
- 18-65 years
- Sex
- All sexes can join (sex assigned at birth, all gender identities).
- Disease stage
- Overweight or obesity due to excess body fat, with a BMI of 27.0-39.9 kg/m^2 and body weight of 60.0 kg (132 lb) or more. Otherwise generally healthy.
- Earlier treatment
- No marketed GLP-1, GIP or glucagon receptor agonist medicine within 90 days before screening. No prescription or non-prescription drugs or herbal medicines that interfere with CYP metabolism within 14 days (or 5 half-lives, whichever is longer) before screening. Routine vitamins, occasional acetaminophen or ibuprofen, and topical medicine are allowed.
Main reasons for not taking part
- Known or suspected allergy to the study medicines or related products
- Any reason not to use caffeine, midazolam or warfarin, as stated in their product information
- Stomach or bowel disorders that could affect how drugs or nutrients are absorbed
- Past major stomach surgery, such as gastrectomy, sleeve gastrectomy or gastric bypass
- A gastrointestinal implant now
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male or female (sex assigned at birth, inclusive of all gender identities)
- Age 18-65 years (both inclusive) at the time of signing the informed consent
- BMI between 27.0-39.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator
- Body weight >=60.0 kg
- Considered to be generally healthy, except for overweight or obesity, based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
Who cannot take part
- Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval), occasional use of acetaminophen, ibuprofen, or topical medication not reaching systemic circulation
- Known or suspected hypersensitivity to study intervention(s) or related products
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator
- History of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant
- Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), or glucagon (GCG) receptor agonism within 90 days before screening
- Any contraindications for the use of caffeine, midazolam, and warfarin used in the study according to Vivarin®, Midazolam®, and warfarin sodium product information
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Altasciences Clinical LA, Inc.Cypress, United StatesContact: Novo NordiskTaking people
About the trial
What the trial wants to find out
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.
The 2 groups in the trial
- UBT251Treatment being tested
UBT251 will be administered subcutaneously with gradual dose escalation during the study.
- Cocktail (Warfarin/Caffeine/Midazolam)Treatment being tested
A cocktail containing warfarin, caffeine, and midazolam will be administered at predefined study visits to evaluate the effect of UBT251 on the pharmacokinetics of CYP enzyme substrates.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label, Single-sequence, Crossover Study Investigating the Influence of UBT251 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes in Participants With Overweight or Obesity
- Plain-language title
- How UBT251 Affects Blood Levels of Midazolam, Caffeine and Warfarin in Overweight or ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07710768, who can take part
- Record updated
- 18 August 2026